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Abstract
Background: Applications of causal inference methods to randomised controlled trial (RCT) data have usually
focused on adjusting for compliance with the randomised intervention rather than on using RCT data to address other,
non-randomised questions. In this paper we review use of causal inference methods to assess the impact of aspects of
patient management other than the randomised intervention in RCTs.
Methods: We identified papers that used causal inference methodology in RCT data from Medline, Premedline, Embase,
Cochrane Library, and Web of Science from 1986 to September 2014, using a forward citation search of five seminal
papers, and a keyword search. We did not include studies where inverse probability weighting was used solely to
balance baseline characteristics, adjust for loss to follow-up or adjust for non-compliance to randomised treatment.
Studies where the exposure could not be assigned were also excluded.
Results: There were 25 papers identified. Nearly half the papers (11/25) estimated the causal effect of concomitant
medication on outcome. The remainder were concerned with post-randomisation treatment regimens (sequential
treatments, n =5 ), effects of treatment timing (n = 2) and treatment dosing or duration (n = 7). Examples were found in
cardiovascular disease (n = 5), HIV (n = 7), cancer (n = 6), mental health (n = 4), paediatrics (n = 2) and transfusion
medicine (n = 1). The most common method implemented was a marginal structural model with inverse probability of
treatment weighting.
Conclusions: Examples of studies which exploit RCT data to address non-randomised questions using causal inference
methodology remain relatively limited, despite the growth in methodological development and increasing utilisation
in observational studies. Further efforts may be needed to promote use of causal methods to address additional clinical
questions within RCTs to maximise their value.
Keywords: Causal inference, RCT, Systematic review, Time-dependent confounding, Marginal structural models,
Marginal nested models, G-computation, G-estimation
Background
Well-powered randomised controlled trials (RCTs) are
widely recognised to provide reliable and unbiased as-
sessments of health interventions; however they require
substantial effort and time, and are usually extremely
expensive to conduct. Despite typically collecting large
quantities of high-quality diverse data, for example, on
laboratory parameters, concomitant medications and ad-
verse events, the main focus of the RCT analysis is fre-
quently a simple intention-to-treat (ITT) analysis of the
randomised intervention.
For analyses other than those comparing randomised
groups, RCT data are subject to the same issues of con-
founding and other potential biases as observational
studies. It is generally well-known that in order to infer
causal associations in such studies we must assume no
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unmeasured confounding; however, when the aim of the
analysis is to examine the effect of a time-varying expos-
ure, the issue becomes more complex. For example, we
may be interested in examining the effect of antiretroviral
therapy (ART) on survival in HIV-infected individuals. In
this situation a patient’s CD4 count is a time-dependent
confounder because it is a time-varying risk factor for sur-
vival, and it predicts when a subject is initiated on therapy.
However, ART will also improve subsequent CD4 counts.
When time-dependent confounders are affected by prior
treatment, adjustment for the time-dependent confounder
in a standard regression model will not appropriately
adjust for the confounding.
The causal inference methods of g-computation [1], g-
estimation [2], and, most commonly, inverse probability
weighting (IPW) of marginal structural models (MSMs)
[3] have been extensively applied in observational studies
for dealing with time-dependent confounding [4–9].
However, their use in RCTs has predominantly focussed
on adjusting for non-compliance with the randomised
intervention [10, 11]. Briefly, as recently summarised by
Naimi, Cole and Kennedy [12], g-computation models
the joint distributions in the observed data to estimate
potential outcomes under different exposure scenarios
(and can be thought of as a longitudinal form of stand-
ardisation [13]). G-estimation relies on the assumption
of no unmeasured confounding to estimate the parame-
ters of a set of structural nested models, in which the ef-
fect of the exposure is broken down incrementally. IPW
of MSMs re-weights the population so that the exposure
becomes independent of time-varying confounders.
The scope of causal methodology is broad and could
be used to exploit clinical trial data to address many
questions beyond analyses of the randomised interven-
tion. For example, existing methodology could allow
questions about effectiveness of concomitant medica-
tions, treatment switching and optimal dynamic treat-
ment strategies (where treatment is altered in response
to patient characteristics that change through time) to
be examined, which would add significant value to the
output of a single RCT.
In this review we aimed to identify published studies
exploiting causal inference methodology to deal with
time-dependent confounding, which used clinical trial
data to examine questions that were not addressed by
the trial randomisation. In doing this, we aimed to gain
an overview of how widely such methodology is used in
the clinical trial context, and identify examples of the
value gained through use of these methods.
Methods
We aimed to identify all studies in any clinical area that
exploited causal inference methodology using clinical
trial data. To achieve this we used both a keyword
search in Medline, Premedline, Embase, Cochrane
Library and Web of Science, from 1986 to September
2014; and a forward citation search of five seminal
papers [1, 3, 9, 14, 15].
Search strategy
We worked with an information specialist/research li-
brarian and a systematic reviewer to develop the search
protocol and our information specialist undertook the
primary search. The details of the protocol are docu-
mented in Additional file 1: Appendix 1. Keywords were
identified by the authors and the information specialist,
and the searches were set up by the information special-
ist using a combination of index headings (where avail-
able) and text word searching. In simplified form, the
keyword search included the following terms: ((time-
varying confounding OR causal effect or parameter OR
causal inference) AND (marginal structural models OR
inverse probability weighting OR g-estimation OR g-for-
mula OR structural nested models)) OR one of the five
key citations. Full details of the searches undertaken and
their results are provided in four parts corresponding to
the Medline, Cochrane, Embase and Web of Science bio-
medical databases, respectively in Additional file 1:
Appendix 2. Searches were conducted on 5 September
2014 and were limited to English language material, ex-
cluding animal studies, case reports, letters, editorials and
economic analyses.
Screening
Papers identified by the search strategy were initially
screened for eligibility by one author using Covidence sys-
tematic review software, Veritas Health Innovation, Mel-
bourne, Australia. Available at (www.covidence.org). The
initial eligibility criteria, based on an abstract screen, were
as follows: (1) use of any of the causal methods defined in
the search and (2) use of clinical trial data. If studies ap-
peared to fulfil those criteria they were obtained in full text
and reviewed for inclusion using a priori exclusion criteria
as follows:
1. Causal method not used
2. Theory only with no application to either real or
simulated data
3. Conference abstracts with no information to allow
assessment of methods
4. Tutorial pieces or observational studies
5. Applications using IPW only to address baseline
imbalances for the comparisons of interest or
informative loss to follow up (or both)
6. Applications using causal inference methods only to
address non-adherence to randomised treatment,
unless the issue of non-compliance was a question
of dosage or duration of treatment and causal
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inference methods were used to infer information
about the optimal dosage/duration
7. Studies of exposures that cannot be assigned e.g.
lifestyle exposures such as body mass index (BMI),
exercise or socio-economic deprivation
8. Theory papers with simulation only
9. Theory papers where the application was in
observational data (if not picked up by exclusion
criterion 4)
During review we identified a small number of papers
that described analysis of a sequential multiple assign-
ment randomised trial (SMART) where IPW based on
randomisation was used to estimate outcomes under
embedded adaptive interventions; these studies were in-
eligible based on criterion 5, but we chose to create an
additional 10th exclusion criterion:
10.Analysis of SMART designs
The full-text screen to establish exclusion based on
criteria 1–4 was performed by a single author, with the
remaining studies reviewed independently by four authors
against criteria 5–10. Any discrepancies were resolved via
a group discussion.
Data extraction and categorisation of the causal question
Data extraction was performed in duplicate by REF and
DK. Following the review aims, the key information ex-
tracted from each study included details of the original
trial (including an overview of the trial population, de-
tails of the randomised comparison); the causal question
of interest and any refinement of the study population in
order to answer this question; the causal method used
and the key references given and both the trial result
and the results of the causal analysis. The full completed
extraction table is available in Additional file 2.
Each paper identified was categorised into one of 4
types of causal question developed during the data ex-
traction phase. This was done to describe the kind of
questions that were already commonly looked at, and
also to identify those less frequently examined, but
with potential to be more widely applied to other sit-
uations in the future. The question types identified
were as follows:
1. Concomitant medication – this covered all studies
looking at the effect of any additional non-
randomised medications or treatments that were
used during the trial period
2. Sequential treatments – encompassing studies
examining the effect of different post-randomisation
treatment regimens, or comparison of/adjustment
for second-line treatments, which were dependent
on response to first-line treatment.
3. Treatment timing – including all studies that looked
at the timing of second-line or post-randomisation
treatments
4. Treatment dosing/duration – studies that examined
the effect of non-randomised dosing strategies or
duration of treatment.
Results
From a total of 2773 studies retrieved (after removing
duplicates) from the search, 1032 were initially screened
for having potential relevance. From these, 114 were
identified for detailed full-text screening, and 26 papers
satisfied all inclusion criteria. The process of study iden-
tification, screening and inclusion is summarised in the
preferred reporting items for systematic reviews and
meta-analyses (PRISMA) flowchart (Fig. 1) [16]. The
PRISMA checklist corresponding to the review is pre-
sented in Additional file 3.
Two of the 26 studies were found to be similar appli-
cations to the same data by the same authors as two
other included studies. To avoid replication, only the
most recent publication for each pair was taken forward
for data extraction, with the earlier publication noted in
the extraction table. Additionally, at the data extraction
point, an additional relevant study was identified from
the reference list of an included study, and was added.
Therefore the final number of included studies was 25.
The papers covered six broad research areas: seven
studies in HIV, six in cancer, five in cardiovascular dis-
ease (two any cardiovascular disease, three diabetes),
four in mental disorders, two in paediatrics and one in
transfusion medicine. The majority of papers (n = 11) es-
timated the causal effect of concomitant medication: 7
looked at treatment dosing/duration, 5 at sequential
treatments, and 2 treatment timing. Table 1 provides a
brief summary of each study, with details of the original
trial question, the causal question examined, the method
used and findings.
Concomitant medication
Of the 11 studies that examined questions about con-
comitant medication, 5 were in cardiovascular disease, 5
in HIV, and 1 in mental health: 4 HIV studies were based
on trials designed to examine efficacy of microbicides
for preventing HIV infection in HIV-seronegative
women in Sub-Saharan Africa (MDP301 [17],
Carraguard [18] and MIRA [19, 20]). The causal ques-
tion of interest in three of these studies was the effect of
hormonal contraceptives (oral and injectable) on acquisi-
tion of HIV infection, with appropriate control for time-
dependent confounders. All studies used some form of
IPW of MSMs to do this. All three studies found similar
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results, in that there was no evidence of an effect of oral
hormonal contraception use on HIV incidence, with some
suggestion of an increased risk with the injectable contra-
ception depo-medroxyprogesterone acetate (DMPA). Al-
though some of the estimates changed slightly, the causal
methods produced broadly similar results to standard ana-
lysis methods in these cases. The fourth study [20] aimed
to look at the effect of the microbicide controlling for con-
dom use as a mediator, and also to estimate the effect of
condom use itself. The final study in HIV, which also ap-
plied IPW, demonstrated a benefit for concomitant use of
cotrimoxazole (an antibiotic) in patients starting ART in
Africa, on mortality and malaria [21].
Data from much larger trials were available in the area
of cardiovascular disease. For example the ARISTOTLE
[22] international mega-trial was designed to assess the
efficacy and safety of apixabin versus warfarin in patients
with atrial fribrilation (AF). The causal inference analysis
aimed to establish the effect of concomitant use of as-
pirin, which was prescribed at the discretion of the treat-
ing physician in addition to the randomised treatment.
As with the majority of papers examining questions
relating to concomitant medication, the method imple-
mented was a marginal structural model (MSM) with
IPW. In this case, the IPW estimates indicated that the
risks of stroke and major bleeding with aspirin use were
underestimated when standard analysis was performed,
increasing the hazard ratio (HR) for stroke from 1.18
(0.94–1.49) to 1.46 (1.15–1.85) and for major bleeding
from 1.41 (1.21–1.66) to 1.65 (1.40–1.94). Three of the
other studies in cardiovascular disease [23–25] and the
mental health application [26] also used MSMs with
IPW. Finally, a study by Sinozaki et al. [27] investigated
the effect of atorvostatin on various cardiovascular
outcomes (including low-density lipoprotein (LDL) chol-
esterol, composite cardiovascular event endpoints,
diabetes-related endpoints) by using both MSMs with
IPW and g-estimation of structural nested models. The
authors found that both methods produced relatively
similar results for all outcomes examined.
Sequential treatments
Analyses to compare treatment sequences were all from
cancer trials. Such trials commonly involve treatment
Fig. 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart. IPW inverse probability weighting, SMART sequential
multiple assignment randomised trial
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Table 1 Summary of included studies, including the disease area, original trial question, category of causal question, methods used
and result of causal analysis
Study Disease area Trial question Causal
category
Causal question Causal method Causal result
summary
Alexander
(2014) [22]
Cardiovascular
disease
Comparative effectiveness
of apixaban vs warfarin in
patients with atrial fibrillation
for risk of cardiovascular and
thromboembolic endpoints
Concomitant
medication
What is the effect of
aspirin use on risk of
cardiovascular and
thromboembolic
endpoints?
MSM with
IPW [9]
Evidence of an
increased risk of
stroke or major
bleeding from
aspirin use as a
concomitant
medication on
top of apixiban
or warfarin
Bobo (2014)
[26]
Mental health Comparative effectiveness
of lithium vs quetiapine on
clinical outcomes in patients
with bipolar disorder
Concomitant
medication
What is the effect of
benzodiazepine use
on core bipolar mood
symptoms?
MSM with
IPW [3]
No statistically
significant effect
of benzodiazepine
use on any of the
outcomes, though
there were
extremely wide
confidence
intervals both
before and after
IPW
Cook (2013)
[43]
Transfusion
medicine
Non inferiority of pathogen
inactivated platelets vs
standard platelets for
successful blood transfusion
(MIRASOL study)
Dosing/
duration
What is the probability
of overall success in
increasing platelet count
over 28 days while
correctly taking into
account number of
transfusions needed?
MSM with
IPW [3, 6, 9]
A reduced
probability of
transfusion success
with increasing
transfusion number
was observed in the
weighted analyses,
but the effect was
smaller than was
observed in the
original trial analysis
Crook (2014)
[17]
HIV Safety and efficacy of a
microbicide gel vs placebo
to prevent HIV transmission
in women with HIV positive
partners in Sub Saharan
Africa (MDP301 trial)
Concomitant
medication
What is the causal effect
of hormonal contraception
(injectable and oral) on
HIV incidence?
MSM with
IPW [3, 14]
Evidence of an
elevated risk of HIV
infection with use
of DMPA but no
other hormonal
contraceptives.
Kataoka (2012)
[23]
Diabetes Efficacy of voglibose,
nateglinide and lifestyle
interventions on changes
in coronary atherosclerosis
in patients with early-stage
diabetes mellitus
Concomitant
medication
What is the effect of
treatment with statins,
ACE inhibitors and ARBs
(considered separately
as three classes of
concomitant medications)
on atheroma progression
as measured by total
lesion length (TLL)?
MSM with
IPW [3, 9]
Use of statins was
estimated to
increase TLL. No
evidence of an
effect of any other
concomitant
medications
examined
Li (2012) [36] HIV Placebo-controlled
comparison of three ART
regimens: ABC/3TC/ZDV,
3TC/ZDV + EFV, ABC/3TC/
ZDV + EFV
Treatment
timing
What is the effect of switching
early (within 8 weeks) vs late
(after 8 weeks) onto a
second-line therapy after first
virologic failure on CD4 count
and other clinical markers of
HIV severity?
IPW [37] Switching early
results in better
clinical outcomes
for all three clinical
measures
examined than
switching late
Lipkovich
(2008) [41]
Mental health Trial 1. Efficacy and safety of
olanzapine vs haloperidol in
terms of clinical scores and
quality of life in acute
bipolar patients Trial 2.
Efficacy and safety of
olanzapine vs risperidone
in terms of clinical scores
in schizophrenic patients
Dosing/
duration
What is the effect of dosage
of olanzapine on change in
disease severity measures?
Estimated separately in
each trial
MSM with
IPW [3, 9, 49]
No strong
evidence of
differences in
response with
changing dose of
olanzapine, though
in one study the
weighted analysis
was suggestive of
a negative dose
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Table 1 Summary of included studies, including the disease area, original trial question, category of causal question, methods used
and result of causal analysis (Continued)
Study Disease area Trial question Causal
category
Causal question Causal method Causal result
summary
effect at weeks 20
and 24 only.
London
(2010) [34]
Cancer Superiority of TOPO vs
TOPO with CTX
(chemotherapy
combinations) for
response to treatment
in recurrent or refractory
neuroblastoma in children.
Sequential
treatments
What is the best
chemotherapy
combination for first
line treatment after
adjusting for the
optimal off-protocol
treatment for survival
at 2 years?
G estimation
of an optimal
Structural
Nested Model
[29, 35]
Under the
assumption that
all patients
received the
optimal off-
protocol therapy,
there were no
detectable
differences
between TOPO
and TOPO with
CTX (2-year survival
40% vs 33%,
p = 0.215)
McCoy
(2013) [19]
HIV Safety and efficacy of
diaphragm, lubricant gel
and condoms vs condoms
alone to prevent HIV
transmission in women in
Sub Saharan Africa
(MIRA study)
Concomitant
medication
What is the effect of
hormonal contraception
(injectable and oral) on
HIV incidence?
MSM with
IPW [51]
No strong evidence
of effect of oral
contraceptives on
HIV transmission,
small suggestion
of increased risk for
injectable
contraception
Morrison
(2012) [18]
HIV Safety and efficacy of a
microbicide gel vs placebo
to prevent HIV transmission
in women in South Africa
(Carraguard study)
Concomitant
medication
What is the effect of
hormonal contraception
(injectable and oral) on
HIV incidence?
MSM with
IPW [3, 6]
No strong evidence
of effect of oral or
injectable
contraceptives on
HIV transmission,
but possibility of an
increased risk with
use of DMPA
Rosenblum
(2009) [20]
HIV Safety and efficacy of
diaphragm, lubricant gel
and condoms vs condoms
alone to prevent HIV
transmission in women in
Sub Saharan Africa
(MIRA study)
Concomitant
medication
What is the effect of the
intervention controlling
for condom use as a
mediator, and what is the
direct effect of condom
use on HIV transmission?
MSM with
IPW [6]
No evidence of a
difference in HIV
risk between
treatment arms
after controlling
for overall condom
use. Condom use
was estimated to
be protective in
both trial arms,
though was only
statistically
significant in
one arm
Rosthøj
(2011) [39]
Cancer Effect of blood counts only
(control) vs blood counts
and pharmacokinetic
parameters to make
therapy decisions on relapse
in acute lymphoblastic
leukaemia in children.
Dosing/
duration
How should dose of oral
therapy be adjusted
(increase, no change,
decrease, pause) in response
to a given white blood cell
count to obtain a future
white blood cell count
within the target range
within a given time frame
(e.g. within two weeks).
How do the estimated
optimal strategies compare
to the original protocol?
History
Adjusted
MSM using
IPW [40]
Optimal strategy
estimated by the
model was broadly
consistent with
the actual protocol
for treatment dosing;
however, where
protocol suggested
moderate reduction
in dose, the MSM
more often
suggested no
change, and where
a moderate increase
in dose was
suggested by
protocol, the MSM
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Table 1 Summary of included studies, including the disease area, original trial question, category of causal question, methods used
and result of causal analysis (Continued)
Study Disease area Trial question Causal
category
Causal question Causal method Causal result
summary
more frequently
suggested a large
increase to be the
optimal choice.
Severus
(2010) [42]
Mental health Efficacy of olanzapine vs
lithium in prevention of
mood episode relapse or
recurrence in patients with
bipolar disorder
Dosing/
duration
What is the effect of dosage
of lithium and olanzapine
on recurrence of symptoms?
MSM with
IPW for
probability of
high/low
dose at each
interval [3]
High and medium
lithium doses
were shown to
reduce risk of
manic/mixed
episode compared
to low doses, but
here was no
evidence of an
effect on risk of
depressive episodes
as confidence
intervals were wider
(although estimates
were similar) Higher
doses of olanzapine
were associated
with lower risk of
depressive episodes
but not manic/
mixed episodes
Shen (2013)
[24] (similar
analysis also
presented in
[52])
Diabetes Efficacy of two drugs
(nateglinine or valsartan)
on conversion to diabetes
and CV outcomes in patients
with impaired glucose
tolerance and other CV risk
factors.
Concomitant
medication
What is the effect of use of
beta blockers, diuretics, and
statins on onset of Type 2
diabetes?
MSM with
IPW [3]
Use of statins and
diuretics found to
increase risk of
diabetes onset
Shinozaki
(2012) [27]
Diabetes Effect of intensive (target
HbA1c 6.9 or less, BMI < 25,
BP < 130/80) vs conventional
treatment (no target levels)
strategies for type 2 diabetes
in elderly patients on risk of
morality, cardiovascular
events and other diabetes
related endpoints
Concomitant
medication
Is there a preventative
effect of atorvastatin on
cardiovascular disease and
on diabetic vascular
complications?
MSM with
IPW, structural
nested failure time
models with
g-estimation
[3, 53]
Atorvastatin
estimated to be
protective against
both cardiovascular
events and
diabetes related
events, though
confidence intervals
for cardiovascular
events were very
wide.
Shortreed
(2012) [38]
Mental health Efficacy and tolerability of
antipsychotic medications
(perphenazine vs
olanzapine/risperidone/
quetiapine/ziprasidone) in
patients with schizophrenia
on time to failure of
treatment (time to first switch)
Treatment
timing
What is the optimal
therapeutic strategy in
terms of initial threshold
of PANSS score (a scale of
psychotic symptoms) to
switch to an atypical
antipsychotic drug over
perphenazine to minimise
schizophrenic symptoms
and maximise quality of life
over 12 months?
Dynamic
MSM with
IPW [54]
No differences
detected between
the different
dynamic regimes
for 12-onth quality
of life. All strategies
predicted
improvements in
PANSS by 12
months. There was
no significant
difference between
12 months PANSS
score between the
strategies of
“always treat with
perphenazine” and
“always treat with
atypical
antipsychotic”, but
it was observed
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Table 1 Summary of included studies, including the disease area, original trial question, category of causal question, methods used
and result of causal analysis (Continued)
Study Disease area Trial question Causal
category
Causal question Causal method Causal result
summary
that if starting
with perphenazine,
PANSS at 12
months was
increased if the
threshold to switch
was higher (i.e.
when the patient
was more likely to
switch).
VandeboscH
(2005) [44]
HIV Safety and efficacy of a
microbicide gel vs placebo
to prevent HIV transmission
in women in Africa
Dosing/
duration
What is the effect of
cumulative gel use on
development of vaginal
lesions prior to HIV diagnosis?
Structural
accelerated
failure time
model [55]
Increased
experimental gel
use was found to
reduce time to
first or any lesion
compared to
placebo gel,
suggesting it may
increase risk of
lesions compared
to placebo gels.
Wahed
(2013) [31]
Cancer Effect of adding all trans
retinoic acid (ATRA),
granulocyte colony
stimulating factor (GCSF) or
both to fludarabine plus
cytosine arabinoside plus
idarubicin (FAI) as a first-line
(induction) therapy on the
probability of success (alive
and in complete remission
at 6 months) in treatment
of acute leukaemia
Sequential
treatments
What is the best combined
induction (randomised) and
salvage (non-randomised)
strategy to improve overall
survival?
G formula
MSM with
IPW [1, 3, 56]
Both methods
gave results
consistent with FAI
plus ATRA being
the best remission
induction therapy.
If patient’s disease
was resistant to
that therapy, then
salvage therapy
options were
equivocal. If a
patient relapsed
after CR with FAI
plus ATRA then
salvage therapy
with HDAC was
superior
Walker
(2010) [21]
HIV Effect of laboratory monitoring
in addition to clinical
monitoring of patients with
HIV in Africa on clinical
endpoints and mortality.
Concomitant
medication
What is the effect of use of
cotrimoxazole on survival,
WHO stage 3 and 4 events,
malaria and CD4 counts in
adults after ART initiation?
MSM with
IPW [3]
Use of cotrimoxazole
was estimated to
improve survival
and reduce malaria
infection in adults
on ART Reduction
in mortality was
greatest in first 18
months of ART
Wang
(2012) [28]
Cancer A sequential multiple
assignment randomised
trial (SMART) designed to
evaluate and compare 12
different sequential rules for
switching from initial
combination chemotherapy
to second chemotherapy
in prostate cancer, in terms
of overall response to
treatment and overall survival.
Sequential
treatments
What is the best overall
strategy to maximise
response to treatment
(“success”) after re-defining
the possible treatment
regimens to be viable
treatment regimens
allowing switches to non-
randomised therapy.
Dynamic
MSM with
IPW [30, 37]
Different
combinations
were estimated to
be optimal based
on different
measures of
“success” Wide
confidence intervals
and large number
of comparisons
meant statistical
comparison
between actual
scores was not
feasible
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switches and second-line therapies that depend upon the
patient’s response to the randomised first-line treatment.
Causal inference analyses are then necessary in order to
establish the optimal combination of treatments. For ex-
ample, Wang et al. [28] used data from a sequential,
multiple assignment, randomised trial (SMART) in ad-
vanced prostate cancer to demonstrate the use of dy-
namic marginal structural models (dMSMs) with IPW
[29, 30] to estimate the overall optimal strategy to maxi-
mise response to treatment. This analysis was different
to those originally conducted and reported for the
trial, because the original analysis did not appropri-
ately account for patients experiencing severe toxicity
or disease progression (at which point non-
randomised treatment decisions were made). A second
application used both g-computation and dMSMs to
Table 1 Summary of included studies, including the disease area, original trial question, category of causal question, methods used
and result of causal analysis (Continued)
Study Disease area Trial question Causal
category
Causal question Causal method Causal result
summary
Zhang
(2012) [25]
Cardiovascular
disease
Effect of felodipine in addition
to hydrochlorothiazide after
6 weeks of therapy (i.e.
intensive blood pressure
reduction vs standard care)
in a population of Chinese
patients at risk of
cardiovascular disease, on
reduction in various
cardiovascular endpoints
(e.g. stroke)
Concomitant
medication
What is the effect of add-on
therapy (in the form of an
increased dose of
hydrochlorothiazide and/or
other antihypertensive
agents excluding calcium
antagonists) in addition to
randomised therapy on trial
outcomes?
MSM with
IPW [9]
Absence of add-on
therapy was found
to be protective
for stroke, all-cause
mortality and all
cardiovascular
events, despite
the add on
therapy reducing
systolic and
diastolic blood
pressure
Zhang
(2013) [33]
(similar
analysis also
presented in
[57])
Cancer Effect of petrexemed in
addition to cisplatin in
patients with malignant
pleural mesothelioma in
terms of time to response
and overall survival
Sequential
treatments
What is the effect of the
randomised first-line
treatment if secondary
treatments and
discontinuation of study
treatment are correctly
adjusted for?
MSM with
IPW [6]
Addition of
petrexemed found
to be beneficial in
comparison to
cisplatin only, with
a smaller HR
estimated via
causal methods
compared to ITT
analysis
Yamaguchi
(2004) [32]
Cancer Superiority of CPT-P vs VDS-P
and non-inferiority of CPT
vs VDS-P (chemotherapy
combinations) for survival in
non-small cell lung cancer
Sequential
treatments
What is the direct effect of
the randomised treatment
for the (CPT-P vs VDS-P) on
survival, accounting for
imbalances in second-line
therapy?
MSM with
IPW, G –estimation
of structural
nested
models
[3, 49, 58]
CPT-P was not
shown to be
beneficial
compared to VDS-
P and no
difference was
observed between
the two different
second line
therapies in terms
of survival
Platt (2012)
[45]
Paediatrics Effect of breast feeding
intervention on prevalence
and length of exclusive
breastfeeding, and weight,
height, and infection rates
by 12 months
Dosing/
duration
What is the effect of length
of breast feeding on
weight (kg) at 12 months?
MSM with
IPW [3]
Fitted mean
12-month weight
(kg) highest for 2
months exclusive
breastfeeding and
lowest for 9–12
months exclusive
breastfeeding
Moodie
(2009) [46]
Paediatrics Effect of breast feeding
intervention on various
12-month endpoints such
as prevalence and length
of exclusive breastfeeding;
and weight, height, and
infection rates in children
Dosing/
duration
What is the effect of length
of breast feeding on weight
(kg) and length (cm) at
12 months?
G-estimation
of structural
nested models
[29, 35, 59]
Breastfeeding to
at least 9 months
optimised
12-month weight
and length
MSM marginal structural model, IPW inverse probability (of treatment) weighting, DMPA depo-medroxyprogesterone acetate, ART antiretroviral therapy, TOPO
topotecan, CTX cyclophosphamide, ABC abacavir, 3TC lamivudine, ZDV zidovudine, EFV efavirenz, CPT-P irinotecan plus cisplatin, VDS-P vindesine plus cisplatin, CPT
irinotecan, ACE angiotensin-converting enzyme, ARBs angiotensin II receptor blockers, PANSS positive and negative syndrome scale, WHO World Health Organisation, HR
hazard ratio, ITT intention to treat
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examine the relative success of different combinations
of induction (first) and salvage (second) treatments for
acute leukaemia [31].
Yamaguchi et al. [32] used both a structural nested
model (SNM) and an MSM with IPW to adjust for re-
ceiving a secondary treatment for non-small-cell lung
cancer. This analysis, rather than identifying an optimal
strategy including different secondary treatment options,
estimated the effect of the randomised comparison
under the assumption that everyone received the same
secondary treatment, and additionally looked at the dir-
ect effect of secondary treatment on survival. A similar
question was addressed via the use of MSM with IPW
by Zhang and Wang [33] in the context of treatment for
malignant pleural mesothelioma, and by London et al.
[34], who used g-estimation of SNMs [35] to compare 2-
year survival rates of two first-line treatment strategies
for children with neuroblastoma, while adjusting for the
optimal off-protocol therapy.
Timing of treatment
Two studies examined questions relating to timing of
treatment. Li [36] used data from a trial comparing three
ART regimens in HIV-infected adults to look at whether
early vs late treatment switch after first virologic failure
had an effect on future viral load and CD4 cell count. The
authors perfomed an analysis based on the theoretical
2001 paper by Murphy, van der Laan and Robins [37],
which presented an IPW estimator for the comparison of
dynamic strategies, and found that early switch after fail-
ure was beneficial compared to late switch. This was in
contrast to an unweighted analysis restricted to patients
who experienced virologic failure, which showed no evi-
dence of a difference between strategies.
The second example was in the area of mental health.
The Clinical Antipsychotic Trials of Intervention Effect-
iveness (CATIE) trial was a large multistage trial aiming
to assess the long-term efficacy and tolerability of newer
atypical antipsychotics compared to standard antipsy-
chotics in the management of schizophrenia. The proto-
col allowed for treatment switching in response to
success of the initial treatment. Shortreed et al. [38] used
a subsample of the trial population to estimate the effect
of different switching thresholds on minimizing schizo-
phrenic symptoms at 12 months, by employing dMSMs
with IPW. The authors found no evidence of differences
between always treating with atypical vs standard anti-
psychotics, but that it was more beneficial to remain on
the standard antipsychotic than switch, no matter what
the observed response to therapy.
Treatment dosing
The Nordic Society for Pediatric Hematology and On-
cology Acute Lymphyblastic Leukaemia (NOPHO-ALL-
92) was a trial in children with ALL, treated long-term
with intensive chemotherapy. It was designed to assess a
new treatment strategy, where at the maintenance phase
patients received oral doses of drugs tailored to their
blood counts, which were monitored weekly. Rosthøj
[39] presents an application of history-adjusted MSMs
[40] to data from this trial, whereby the estimated opti-
mal dosing strategies were examined and compared to
those set out by the protocol. In general, the optimal
strategy estimated by the model was broadly consistent
with the actual protocol for treatment dosing. However,
where the protocol suggested a moderate reduction in
dose, the MSM more often suggested no change, and
where a moderate increase in dose was suggested by
protocol, the MSM more frequently suggested a large in-
crease to be the optimal choice.
In mental health studies, patients not only switch be-
tween different drugs but also receive dose-adjustments,
which are often at the clinician’s discretion, even in clin-
ical trial settings. Such dose adjustments through time
will depend on many factors, which have likely been in-
fluenced by prior dosing decisions – a typical example of
time-dependent confounding affected by prior treat-
ment. Two studies [41, 42] used data from three flexible
dose trials in acutely ill patients with bipolar disorder
and schizophrenia. Both fitted MSMs with IPW to cor-
rectly adjust for confounding.
Another application of IPW to investigate dosing was
found in transfusion medicine with repeated binary out-
comes [43]. In the MIRASOL study, two platelet types
were compared for non-inferiority in terms of overall
successful transfusion for 28 days after surgery, where
multiple transfusions could be performed. However, the
effect of transfusion number on the probability of suc-
cess of the transfusion (which was an intended second-
ary analysis of the trial) could not be correctly estimated
without the use of causal methodology since those not
responding to their first transfusions were more likely to
need more, resulting in an estimated negative effect of
multiple transfusions. The authors showed that this ef-
fect was attenuated by the use of causal methods.
An analysis in HIV infection, again based on data from
a trial of a microbicidal gel, examined the effect of “dos-
ing” by examining cumulative exposure to the experi-
mental gel in relation to development of lesions [44].
This study was motivated by the original trial finding
that the experimental gel actually increased HIV trans-
mission. To see if the reason for such a finding was due
to the gel causing lesions, causal methods were neces-
sary to estimate the effect of cumulative gel use on le-
sion development, with appropriate control for the
number of sexual acts, which itself likely influences le-
sion development. The authors used structural, acceler-
ated failure-time models extended to deal with multiple
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events and found that the survival time to both first, and
all lesions, was shorter in the experimental arm than the
placebo arm, and that the relative difference in survival
time between arms increased as gel dose increased.
Finally, two studies used data from the same cluster
randomised trial of a breastfeeding intervention to look
at the effect of duration of breast feeding on infant
weight and length at 12 months. To adjust for con-
founders of the association between length of breast-
feeding and infant weight and length, one study used
MSM with IPW [45], and the other g-estimation of
SNMs [46]. In a previous publication, a non-causal ana-
lysis had estimated that both weight-for-age and length-
for-age were higher in the first 3 months in babies
breastfed for more than 3 months and more than
6 months, respectively, compared to those weaned be-
fore 1 month. From 6 months onwards, longer exposure
to breastfeeding appeared to reduce weight-for-age and
length-for-age compared to early weaning. The MSM es-
timated that mean weight at 12 months was highest for
children exclusively breastfed to 2 months. The expected
12-month weight was observed to reduce as the length
of breastfeeding increased to 9 months. The estimated
weight at 12 months was the same for 9 or 12 months
duration of breastfeeding. In contrast, using SNMs it
was found that continuing to 9 months would increase
weight and length, but that additional breastfeeding be-
yond 9 months would not increase 12-month weight or
length further. The authors of [46] discuss potential rea-
sons for the difference in results between the two causal
methods, with one possible explanation being the way
the two methods handle subjects with missing data.
Discussion
There are applications of causal methodology to data
from RCTs across a number of disease areas and re-
search questions, though the number of such applica-
tions is fairly low. The most commonly addressed
question type is the effect of concomitant medication on
outcome, with about half the papers studying this. This
is likely because it is a common question of interest
when examining clinical trial data; particularly, for trials
in chronic disease populations, it is unlikely that the ran-
domised treatment will be the only therapy being taken
for disease management or to control other comorbidi-
ties throughout follow-up. Second, it is a question that
can be easily addressed, given enough prescribing vari-
ability, through the use of MSM with IPW, which, with
its link to sampling weights and propensity score weight-
ing, is perhaps the most intuitive and easily implemented
of the causal methods.
The use of causal methods to look at dosing (seven
studies), and sequential treatments (six studies) was less
common. It is possible that this is due to a lack of
variability in dosing or second-line treatment options in
the specified trial protocols, or because fewer data are
collected if a patient deviates from the trial protocol.
The sequential treatments question was most common
in cancer trials, likely due to this being a disease in
which interest lies in the success of a complete treat-
ment strategy rather than the direct effectiveness of indi-
vidual treatments.
Questions relating to timing of treatment were not fre-
quently examined. Applications were limited to one
paper in HIV, which looked at early versus late treat-
ment switch after the first virologic failure, and one
paper in mental health, which compared switching strat-
egies based on a single measure of treatment perform-
ance. Other timing questions that could also be
investigated via the use of the same methodology could
be related to the level of laboratory or clinical measures
at which treatment should be initiated rather than inten-
sified/switched, or could be extended to compare more
complex switching rules containing multiple variables.
For example, subsequently to this review Ford et al.
[47] used dynamic MSMs to investigate optimal treat-
ment strategies for switching patients on ART includ-
ing when to define failure (based on CD4 threshold
or clinical event history) and how frequently to moni-
tor CD4 count.
The ability to model these dynamic strategies relies on
observing multiple strategies within the study data. In
many settings, trials allow for non-randomised second-
ary treatments if the randomised treatment is considered
to have failed, enabling researchers to investigate se-
quencing questions provided the necessary data are col-
lected after initial failure. However, if the threshold for
“failure” of treatment is clearly specified in the protocol,
there may not be enough variation in the observed treat-
ment strategies to examine questions of treatment tim-
ing. Noting the exception already described above [47],
it may be the case that, for questions of treatment tim-
ing, causal analysis of observational data (in which
greater variation in levels of key measures that define
“failure” at the time of treatment switching will be ob-
served) are more useful for examining questions of treat-
ment timing and generating hypotheses for subsequent
trials of treatment strategies.
Of the 25 papers identified, 12 came from medical
journals. Of these, 10 were questions on concomitant
medication using IPW of MSMs. It therefore appears
that the current literature, particularly for questions
other than those on the effects of non-randomised treat-
ments, remains focussed towards those interested in
statistical methodology. It may be that those focussed to-
wards clinical research and trials may still lack awareness
of the types of alternative questions that can be an-
swered, and of alternatives to IPW of MSMs; or that the
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methodology is still limited in terms of its ability to draw
strong clinical conclusions and is therefore of less inter-
est to medical journals. Within cancer, the literature
highlights the need for causal methodology. For ex-
ample, an article in the Journal of Thoracic Disease [48]
discusses the problem of time-varying confounding in
clinical trials exploring the long-term effects of first-line
treatment in patients with cancer and warns about the
lack of analyses implementing causal methodology to ad-
equately and appropriately assess treatment effects. One
research area in which causal methods seem more estab-
lished is HIV. Many of the early papers describing and
applying causal inference methods had applications in
either trial or observational data in this disease [3, 6, 49,
50], and as such it has had longer exposure to such
methods, resulting in wider uptake. Therefore although
it seems that researchers in specific disease areas are be-
coming aware of the need for causal methods, further ef-
forts may be necessary to promote dissemination and
uptake of such techniques into other therapeutic areas
where they may be highly beneficial in gaining additional
insights from existing trial data, rather than being exclu-
sively used with observational data.
More broadly, a practical difficulty that may limit ap-
plication of the methods in RCT settings may include
the lack of power to estimate non-randomised effects.
There is little methodological work examining power for
causal analyses, and as such researchers may be unable
to justify their use when developing analysis plans. In
addition, lack of power in such analyses may often lead
to inconclusive results, as is the case in many of the
studies presented in this review. One exception to this
was the study by Walker et al. [21]. In this case, the au-
thors found strong evidence that cotrimoxazole use re-
duced mortality in the first 72 weeks after starting ART.
However, overall, the lack of conclusive findings in many
applications may result in scepticism of the benefits of
causal methods, and in publication bias. As such, this re-
view may actually underestimate how often causal
methods are being applied in RCT settings, but without
publication of results, the additional knowledge that may
be gained from existing trials to generate hypotheses for
subsequent clinical trials may be lost.
Strengths of the systematic review were its pre-defined
protocol with a comprehensive search strategy. Further
to this, the studies were reviewed against the pre-
determined inclusion and exclusion criteria by four re-
searchers, in order to minimise subjectivity. There is the
possibility that a small number of relevant papers were
missed due to restricting the search to English-language
articles. However, despite this limitation, the final selec-
tion of papers is likely to provide a representative picture
of the current use of causal methodology in RCTs be-
yond their use to adjust for compliance to randomised
therapy or loss to follow up. Detailed data were taken
from each paper to ensure good understanding of the
motivation and methods used for each causal question
examined and this enabled us to clearly describe how
and where causal methods are being used within trials.
The inclusion of more methodogical papers where an
example application was given may slightly overestimate
the use of the methods in some disease areas. For ex-
ample, two cancer papers [32, 33] were mostly theoret-
ical. However, their inclusion is still beneficial in terms
of our aim of identifying areas in which causal methods
are relevant and have potential.
By selecting studies that had used causal methodology
to deal with issues of time-dependent confounding, it is
likely that the methodology used was appropriate to an-
swer the question of interest; however, we did not con-
duct any formal quality assessment of the included
studies. For example, we did not examine whether the
authors discussed (or conducted) sensitivity analyses to
investigate whether or not necessary assumptions
needed for valid causal inference were met. Although
such quality assessment would have been important if
we were attempting to use the studies to synthesise the
evidence on a particular causal question, or to evaluate
how rigorously such methodology is currently applied,
for the main aims of this review we do not consider it to
be a significant limitation. The main limitation is that
our search was conducted in September 2014, which
leaves the possibility that some more recent studies were
missed. To assess this we conducted an updated search
from January 2014 to September 2017 using the Web of
Science database only, as this database provided 52% of
the 2773 references found in the original search. After
excluding references that were already in the original
search to September 2014, there were 686 new records
for screening. A brief screen of the first 250 articles
(when ordered alphabetically by first author) identified
17 potentially relevant studies of which at further in-
spection, only one met the original inclusion criteria
[47]. This equates to a 0.4% hit rate for this subsample
of the updated search, compared to an overall rate of
0.9% in the original search, suggesting that the uptake of
causal methodology in RCTs is unlikely to have substan-
tially increased since the review was conducted.
Conclusion
In conclusion, the use of causal methodology to answer
additional questions from RCT data remains relatively
limited. In particular, the use of the g-methods is min-
imal, potentially due to the more intuitive nature of IPW
of MSMs making this the preferred approach for applied
examples. The current applications and examples of
causal methodology show that the methods can be
implemented to answer questions on the use of
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concomitant medications, dosing strategies and treat-
ment sequences and in some cases can provide clinically
useful answers to questions not originally examined by
the trial. It is possible that their use as a way to enhance
current clinical trial data is under-emphasised due to an
overall lack of clinically significant findings in the
current literature. Further methodological work in terms
of power calculations for causal methodology may be
beneficial to enable trials to be designed to power sec-
ondary analyses, or at least make potential power issues
more transparent. Further to this, there needs to be
wider and more focussed efforts to make researchers
more aware of causal methods, of how they can be im-
plemented, and of their potential to add value to RCTs.
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